Yourgene Health PLC Yourgene Genomic Services collaboration with Cytox
21 October 2020 - 5:00PM
RNS Non-Regulatory
TIDMYGEN
Yourgene Health PLC
21 October 2020
Yourgene Health plc
("Yourgene Health" or the "Company")
Yourgene Genomic Services collaboration with Cytox
Partnership with Cytox to enable clinical access to
genoSCORE(TM) - a new genetic test to determine the risk of
developing Alzheimer's disease
Manchester, UK - 21 October 2020: Yourgene Health (AIM: YGEN), a
leading international molecular diagnostics group, announces a new
collaboration between the recently launched Yourgene Genomic
Services ("YGS") and Cytox Ltd ("Cytox"), for a beta-testing
genomic study on their genetic risk test for Alzheimer's disease
("AD").
Under the YGS offering, Yourgene Health will validate and verify
the performance of the Cytox genoSCORE-LAB(1) process for both
whole blood and saliva samples, to ensure the robust and
reproducible detection of genotypes necessary to calculate
individual polygenic risk scoring ("PRS").
YGS was launched recently to bring together a number of
Yourgene's core capabilities, creating a service business that
supports partners at the preclinical, clinical and post-market
stages as they develop, manufacture, obtain regulatory approval and
commercialise new products and services. Cytox specialises in
developing and commercialising PRS algorithms to characterise an
individual's genetic risk for developing AD. Both parties are
exploring a potential partnership to provide genoSCORE as a
clinical testing service from Yourgene's UK laboratory in
Manchester next year once Cytox have formally launched the
test.
Lyn Rees, CEO of Yourgene Health plc, commented: "This is an
exciting partnership for Yourgene Genomic Services and a fine
example of our ever-increasing product and service offering. We
already have a well-established relationship with Cytox and are
looking forward to working with them on this progressive
technology. I look forward to updating shareholders in the near
future."
Dr. Richard Pither, CEO of Cytox, commented: "In Europe there
are an estimated 1.6 million new cases of dementia each year, of
which 800,000 are Alzheimer's disease. As part of the disease
management pathway, we anticipate clinicians adopting genoSCORE-LAB
not only as an early test for patients concerned about future AD
risk, but also to provide additional insight into potential disease
progression in existing patients. We look forward to working with
the Yourgene team on this initial Beta testing study ahead of our
product launch."
(1) genoSCORE(TM)-LAB - genetic test to predict future risk of
developing AD. The test, which uses a simple blood or saliva
sample, analyses patient genotypes against an array of about
114,000 single nucleotide polymorphisms (SNPs) that have been
associated with AD. As such, the test generates a patient-specific
PRS .
Yourgene Health plc Tel: +44 (0)161 669 8122
Lyn Rees, Chief Executive Officer investors@yourgene-health.com
Barry Hextall, Chief Financial Officer
Joanne Cross, Director of Marketing
N+1 Singer (Joint Corporate Broker) Tel: +44 (0)20 7496 3000
Aubrey Powell / Tom Salvesen / George
Tzimas
Stifel Nicolaus Europe Limited (Joint Tel: +44 (0)20 7710 7600
Corporate Broker)
Nicholas Moore / Matthew Blawat / Ben
Maddison
Walbrook PR Ltd (Media and Investor Tel: +44 (0)20 7933 8780 or yourgene@walbrookpr.com
Relations)
Paul McManus / Lianne Cawthorne Mob: 07980 541 893 / Mob: 07584
391 303
About Yourgene Health
Yourgene Health is an international molecular diagnostics group
which develops and commercialises genetic products and services.
The group works in partnership with global leaders in DNA
technology to advance diagnostic science.
Yourgene develops and commercialises simple and accurate
molecular diagnostic solutions, for reproductive health and
precision medicine. The Group's products include non-invasive
prenatal tests (NIPT) for Down's Syndrome and other genetic
disorders, Cystic Fibrosis screening tests, invasive rapid
aneuploidy tests, male infertility tests and genetic disease tests.
Yourgene's commercial footprint is already established in the UK,
Europe, the Middle East, Africa and Asia.
Our product development, research service and commercial
capabilities extend across the lifecycle of genetic test
development including regulatory submissions. Through our technical
expertise and partnerships, Yourgene Health is also extending its
genetic testing offering into oncology.
Yourgene Health is headquartered in Manchester, UK with offices
in Taipei and Singapore, and is listed on the London Stock
Exchange's AIM market under the ticker "YGEN". For more information
visit www.yourgene-health.com and follow us on twitter
@Yourgene_Health.
About Cytox ( www.cytoxgroup.com )
Without new drug therapies, the economic and healthcare cost
burden of dementia - including Alzheimer's disease - is estimated
to exceed $1tn per year in the next decade(1) . Alzheimer's - a
highly complex disease with risk factors based in genetics,
lifestyle, age, and environment - has seen no new approved drug
therapy since 2003; and clinical trial failure rates run at 99.6%.
Cytox's products genoSCORE(TM) and genoTOR(TM) use Polygenic Risk
Scoring (PRS) to improve clinical trial outcomes through patient
stratification and the genetic characterisation of Alzheimer's
disease.
Reference:
1. World Alzheimer's Report 2015
www.alz.co.uk/research/WorldAlzheimerReport2015.pdf
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRAEAKEEALKEFFA
(END) Dow Jones Newswires
October 21, 2020 02:00 ET (06:00 GMT)
Premaitha (LSE:NIPT)
Historical Stock Chart
From Jun 2024 to Jul 2024
Premaitha (LSE:NIPT)
Historical Stock Chart
From Jul 2023 to Jul 2024